secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenon Pharmaceuticals Inc. (XENE)
CIK:        0001582313
Form:       8-K
Filed at:   2022-03-10T23:59:59+00:00
Accession:  0001564590-22-009639
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenon: director Hayden not standing for re-election; Pimstone to become Chair; exec comp approved
--------------------------------------------------------------------------------

- Michael Hayden will not stand for re-election at June 1, 2022 annual meeting; no disagreement with company.
- Board appointed Dr. Pimstone as Chair of the Board, effective subject to his re-election as director.
- 2022 base salaries: Pimstone $525k, Mortimer $594k, Aulin $425k; retroactive to Jan 1, 2022.
- 2022 performance goals include XEN1101 Phase 3 start and MDD proof-of-concept trial initiation.
- 2021 non-equity incentive payments: Pimstone $450k, Mortimer $400k, Aulin $155k (in USD).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582313/000156459022009639/0001564590-22-009639-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582313/000156459022009639/xene-8k_20220309.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-009639

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer